for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Perrigo Company PLC

PRGO.N

Latest Trade

53.81USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

36.33

 - 

75.42

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
53.81
Open
--
Volume
--
3M AVG Volume
26.60
Today's High
--
Today's Low
--
52 Week High
75.42
52 Week Low
36.33
Shares Out (MIL)
136.05
Market Cap (MIL)
7,217.70
Forward P/E
13.49
Dividend (Yield %)
1.58

Next Event

Q3 2019 Perrigo Company PLC Earnings Call

Latest Developments

More

Perrigo Advances Consumer Self-Care Growth Strategy With Acquisition Of Prevacid 24Hr

Perrigo Announces Patent Litigation Settlement For The Generic Version Of Nascobal Nasal Spray

Starboard Value LP Says It Intends To Remain Shareholder Of Perrigo

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Perrigo Company PLC

Perrigo Company PLC (Perrigo), formerly Perrigo Company Limited, is an over-the-counter (OTC) consumer goods and specialty pharmaceutical company. The Company's segments include Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx) and Specialty Sciences. It manufactures OTC healthcare products and supplies infant formulas for the store brand market. It is also a provider of generic extended topical prescription products. The CHC segment is focused on the sale of OTC store brand products. The BCH segment develops, manufactures, markets and distributes various European OTC brands. The Rx segment develops, manufactures and markets a portfolio of generic and specialty pharmaceutical prescription drugs. The Specialty Sciences segment consists of assets focused on the treatment of multiple sclerosis, specifically in connection with the drug, Tysabri.

Industry

Biotechnology & Drugs

Contact Info

The Sharp Building, Hogan Place

+353.1.7094000

https://www.perrigo.com/

Executive Leadership

Murray S. Kessler

President, Chief Executive Officer, Director

Raymond P. Silcock

Chief Financial Officer

James R. Michaud

Chief Human Resource Officer, Executive Vice President

Thomas M. Farrington

Executive Vice President, Chief Information Officer

James E. Dillard

Executive Vice President, Chief Scientific Officer

Key Stats

2.77 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

5.2K

2017

4.9K

2018

4.7K

2019(E)

4.8K
EPS (USD)

2016

5.070

2017

4.930

2018

4.550

2019(E)

3.933
Price To Earnings (TTM)
82.70
Price To Sales (TTM)
1.55
Price To Book (MRQ)
1.26
Price To Cash Flow (TTM)
14.91
Total Debt To Equity (MRQ)
60.83
LT Debt To Equity (MRQ)
53.86
Return on Investment (TTM)
0.90
Return on Equity (TTM)
0.77

Latest News

Latest News

BRIEF-Aspen's Infant Formula Unit Is Said To Draw Reckitt, Perrigo - Bloomberg

* ASPEN'S INFANT FORMULA UNIT IS SAID TO DRAW RECKITT, PERRIGO - BLOOMBERG, CITING SOURCES

BRIEF-Perrigo Says Terminated Existing Credit Agreements

* PERRIGO - EFFECTIVE MARCH 8, CO TERMINATED EXISTING CREDIT AGREEMENTS & REPLACED THEM WITH A NEW SENIOR UNSECURED REVOLVING AND TERM LOAN CREDIT AGREEMENT

BRIEF-Perrigo - John Hendrickson's 2017 Total Compensation $8.3 Million Versus $5.8 Million In 2016

* PERRIGO COMPANY PLC CEO JOHN HENDRICKSON'S 2017 TOTAL COMPENSATION $8.3 MILLION VERSUS $5.8 MILLION IN 2016 - SEC FILING

BRIEF-Perrigo CEO Buys 7,500 Shares Of Co's Ordinary Shares On March 5

* PERRIGO CEO UWE ROEHRHOFF REPORTS PURCHASE OF 7,500 SHARES OF CO'S ORDINARY SHARES ON MARCH 5 - SEC FILING Source text: (http://bit.ly/2Fpn04Z) Further company coverage:

BRIEF-Perrigo Announces Final FDA Approval And Planned Launch For The Store Brand OTC Equivalent Of Mucinex DM Maximum Strength Extended Release Tablets

* PERRIGO ANNOUNCES FINAL FDA APPROVAL AND PLANNED LAUNCH FOR THE STORE BRAND OTC EQUIVALENT OF MUCINEX® DM MAXIMUM STRENGTH EXTENDED RELEASE TABLETS

BRIEF-Perrigo Company Q4 GAAP Earnings Per Share $0.52

* REPORTS FOURTH QUARTER & CALENDAR YEAR 2017 FINANCIAL RESULTS

BRIEF-Perrigo Company Reports Select Preliminary Unaudited 2017 Financial Results

* REPORTS SELECT PRELIMINARY UNAUDITED CALENDAR YEAR 2017 FINANCIAL RESULTS

BRIEF-Perrigo Confirms Patent Challenge For Generic Version Of Finacea Foam, 15%

* PERRIGO CONFIRMS PATENT CHALLENGE FOR GENERIC VERSION OF FINACEA® FOAM, 15%

BRIEF-Perrigo Appoints Ronald Winowiecki As CFO

* PERRIGO APPOINTS RONALD L. WINOWIECKI AS CHIEF FINANCIAL OFFICER

BRIEF-Perrigo Announces Tentative FDA Approval For The Generic Version Of Soolantra Cream, 1%

* PERRIGO ANNOUNCES TENTATIVE FDA APPROVAL FOR THE GENERIC VERSION OF SOOLANTRA® CREAM, 1% Source text for Eikon: Further company coverage:

BRIEF-Perrigo Announces Final FDA Approval Of A Generic Version Of Estrace Cream

* PERRIGO ANNOUNCES FINAL FDA APPROVAL OF A GENERIC VERSION OF ESTRACE CREAM

BRIEF-Perrigo Announces Final FDA Approval And Launch Of An AB Rated Generic Version Of Epiduo Gel

* PERRIGO ANNOUNCES FINAL FDA APPROVAL AND LAUNCH OF AN AB RATED GENERIC VERSION OF EPIDUO GEL Source text for Eikon: Further company coverage:

BRIEF-Perrigo Says In Connection With Uwe Röhrhoff's Appointment As CEO, Co's Unit Perrigo DAC Entered Into Employment Agreement With Him

* PERRIGO COMPANY - IN CONNECTION WITH UWE RÖHRHOFF'S APPOINTMENT AS CEO, CO'S UNIT PERRIGO DAC ENTERED INTO AN EMPLOYMENT AGREEMENT WITH HIM

Perrigo hires Gerresheimer ex-boss Rohrhoff as new CEO

Generic drugmaker Perrigo Company Plc appointed Uwe Rohrhoff, former CEO of Gerresheimer AG, as its new chief executive, the company said on Monday.

Perrigo hires Gerresheimer ex-boss Rohrhoff as new CEO

Generic drugmaker Perrigo Company Plc appointed former Gerresheimer AG Chief Executive Uwe Rohrhoff as its new president and CEO, the company said on Monday.

BRIEF-Perrigo appoints Uwe Röhrhoff as CEO

* PERRIGO APPOINTS UWE RÖHRHOFF AS PRESIDENT & CHIEF EXECUTIVE OFFICER

BRIEF-Perrigo Announces Tentative FDA Approval For The Generic Version Of Prolensa Ophthalmic Solution 0.07%

* PERRIGO ANNOUNCES TENTATIVE FDA APPROVAL FOR THE GENERIC VERSION OF PROLENSA® OPHTHALMIC SOLUTION 0.07% Source text for Eikon: Further company coverage:

BRIEF-Perrigo Announces The Launch Of An AB Rated Generic Version Of Mycolog II Cream

* PERRIGO ANNOUNCES THE LAUNCH OF AN AB RATED GENERIC VERSION OF MYCOLOG II CREAM Source text for Eikon: Further company coverage:

BRIEF-Perrigo Company ‍Launch AB Rated Generic Version Of Exalgo 32mg

* PERRIGO COMPANY PLC - LAUNCH OF AN AB RATED GENERIC VERSION OF EXALGO 32MG EXTENDED RELEASE TABLETS C-II Source text for Eikon: Further company coverage:

BRIEF-Perrigo Company completes divestiture of API business for $110 million

* Perrigo Company completes divestiture of API business for $110 million Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up